1. Home
  2. EVO vs FTH Comparison

EVO vs FTH Comparison

Compare EVO & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$1.96

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Faeth Therapeutics Inc. Common Stock

FTH

Faeth Therapeutics Inc. Common Stock

N/A

Current Price

$28.03

Market Cap

860.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EVO
FTH
Founded
1993
N/A
Country
Germany
United States
Employees
4553
29
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
860.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EVO
FTH
Price
$1.96
$28.03
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
44.2K
229.5K
Earning Date
04-08-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.37
N/A
Revenue Next Year
$10.05
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.94
$17.50
52 Week High
$4.42
$37.90

Technical Indicators

Market Signals
Indicator
EVO
FTH
Relative Strength Index (RSI) 25.35 53.94
Support Level N/A $22.06
Resistance Level $3.36 $37.90
Average True Range (ATR) 0.10 4.11
MACD -0.05 -0.34
Stochastic Oscillator 1.02 33.22

Price Performance

Historical Comparison
EVO
FTH

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

About FTH Faeth Therapeutics Inc. Common Stock

Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.

Share on Social Networks: